TAVALISSE

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Apr 17, 2018

   8 yr 4 mo ago

2. Patent 8211889 expires

   Listed drug substance patent expiration.

   Jan 19, 2026

   5 mo ago

3. Patent 9266912 expires

   Listed method-of-use patent (U-2294) expiration.

   Jan 19, 2026

   5 mo ago

4. Patent RE48898 expires

   Listed drug product patent expiration.

   Jan 19, 2026

   5 mo ago

5. Patent 7538108 expires

   Listed drug substance patent expiration.

   Mar 28, 2026

   3 mo ago

6. Patent 7989448 expires

   Listed drug substance patent expiration.

   Jun 12, 2026

   7 d ago

7. Patent 8163902 expires

   Listed drug substance patent expiration.

   Jun 17, 2026

   2 d ago

8. Patent 8445485 expires

   Listed drug product patent expiration.

   Jun 17, 2026

   2 d ago

9. Patent 8912170 expires

   Listed method-of-use patent (U-2294) expiration.

   Jun 17, 2026

   2 d ago

10. Patent 9283238 expires

    Listed method-of-use patent (U-2294) expiration.

    Jun 17, 2026

    2 d ago

11. Today

12. Patent 8652492 expires

    Listed drug product patent expiration.

    Nov 06, 2028

    in 2 yr 5 mo

13. Patent 8263122 expires

    Listed drug product patent expiration.

    Nov 24, 2030

    in 4 yr 6 mo

14. Patent 7449458 expires

    Listed drug substance patent expiration.

    Sep 04, 2031

    in 5 yr 3 mo

15. Patent 8771648 expires

    Listed drug product patent expiration.

    Jul 27, 2032

    in 6 yr 2 mo

16. Patent 8951504 expires

    Listed method-of-use patent (U-2294) expiration.

    Jul 27, 2032

    in 6 yr 2 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (14)